Skip to main content
Clinical Trials/EUCTR2009-017039-16-FR
EUCTR2009-017039-16-FRActive, not recruitingPhase 1

Effect of strontium ranelate (2g per day) in the management of lower limb fractures with delayed-union or non union: an international open label study in patients with osteoporosis

Institut de Recherches Internationales Servier0 sites40 target enrollmentStarted: April 2, 2010Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
40

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • Osteoporotic patients,
  • With a fracture of the lower limbs with delayed union, defined as an absence of radiological full union after 6 months according to investigator’s opinion OR withNon-union defined as non-union for at least 6 months and no sign of radiological healing or bone reaction since at least 3 months,
  • Ambulatory prio to the qualifying fracture.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • ­Not pathological fracture,
  • Bone-related disease other than osteoporosis,
  • Septic or synovial or congenital pseudarthrosis,
  • Fracture with a fracture gap, after reduction or treatment, greater than more the half the width of the affected bone,
  • Concomitant treatments interfering with bone metabolism,
  • History of venous thrombo-embolism,
  • History of intolerance, allergy or hypersensitivity to strontium ranelate,
  • Contraindication to Calperos D3.

Investigators

Similar Trials

Active, not recruiting
Not Applicable
Effect of strontium ranelate in the management of long bone fractures.Delayed and non-united fracturesMedDRA version: 14.1Level: PTClassification code 10017088Term: Fracture nonunionSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 14.1Level: PTClassification code 10017081Term: Fracture delayed unionSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2009-017039-16-HUInstitut de Recherches Internationales Servier40
Active, not recruiting
Not Applicable
Efficacy of strontium ranelate in the management of long bone fracturesDelayed and non-united fracturesMedDRA version: 14.1Level: PTClassification code 10017088Term: Fracture nonunionSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 14.1Level: PTClassification code 10017081Term: Fracture delayed unionSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2009-017039-16-CZInstitut de Recherches Internationales Servier40
Active, not recruiting
Not Applicable
Effect of strontium ranelate in the management of long bone fracturesDelayed and non-united fracturesMedDRA version: 14.0Level: PTClassification code 10017081Term: Fracture delayed unionSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 14.0Level: PTClassification code 10017088Term: Fracture nonunionSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disorders
EUCTR2009-017039-16-DEInstitut de Recherches Internationales Servier40
Active, not recruiting
Not Applicable
Effect of strontium ranelate (2g per day) in the management of lower limb fractures with delayed-union or non union: an international open label study in patients with osteoporosis - ND
EUCTR2009-017039-16-ITINSTITUT DE RECHERCHES INTERNATIONALES SERVIER40
Active, not recruiting
Not Applicable
The efficacy and safety of 2g strontium ranelate in the treatment of male osteoporosis.A prospective multicentre, international, double-blind, placebo-controlled study with a treatment duration of 2 years and the main study analysis after 1 year. - MALEOmale osteoporosisMedDRA version: 9.1Level: PTClassification code 10031282Term: Osteoporosis
EUCTR2006-006086-16-BEInstitut de Recherches Internationales Servier221